Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230863 · ClinicalTrials.gov registry record · NA
Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive Impairment
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT04230863: Completed NA study, sponsored by Vanderbilt University Medical Center.
NCT04230863 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230863, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).
Primary Outcome
Assess the percentage of enrolled participants who completed of the 40-hour nCCR treatment
Interventions
- BEHAVIORAL Neuroplasticity-based Computerized Cognitive Remediation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2021-06-30 |
| Phase | NA |
What the finished NCT04230863 record still lists
NCT04230863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Neuroplasticity-based Computerized Cognitive Remediation is the first listed.
NCT04230863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04230863 about?
NCT04230863 is a clinical study titled "Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive Impairment". The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).
What is the current status of trial NCT04230863?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2020-02-17. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04230863?
The interventions under investigation include: Neuroplasticity-based Computerized Cognitive Remediation (BEHAVIORAL).
Who is sponsoring clinical trial NCT04230863?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04230863's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI